Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats

Neurobiology of Disease

Volumn 74, Issue , 2015, Pages 295-304

  Martinez, A A ^a   Morgese, M G ^a,c   Pisanu, A ^b   Macheda, T ^a   Paquette, M A ^a   Seillier, A ^a   Cassano, T ^c   Carta, A R ^d   Giuffrida, A ^a  

^a University of Texas Health Science Center   (United States)

^b CNR   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Cannabinoid; Dyskinesia; Levodopa; Parkinson's disease; PPAR ; Rosiglitazone

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; ANANDAMIDE; BENSERAZIDE; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DOPAMINE; DYNORPHIN; EARLY GROWTH RESPONSE FACTOR 1; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE; N OLEOYLETHANOLAMINE; OXIDOPAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIPARKINSON AGENT; EGR1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG TARGETING; DYSKINESIA; ENZYME PHOSPHORYLATION; MALE; NONHUMAN; RAT; RECEPTOR UPREGULATION; AGONISTS; ANIMAL; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; METABOLISM; PARKINSONIAN DISORDERS; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; WISTAR RAT;

ANIMALS; ANTI-DYSKINESIA AGENTS; CORPUS STRIATUM; DOPAMINE; DYNORPHINS; DYSKINESIA, DRUG-INDUCED; EARLY GROWTH RESPONSE PROTEIN 1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; LEVODOPA; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHOSPHORYLATION; PPAR GAMMA; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 84919359735     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.11.024     Document Type: Article

References (72)

1. Akasaki Y., et al. A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J. Biol. Chem. 2006, 281(10):6165-6174.
2. Andersson M., Hilbertson A., Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 1999, 6(6):461-474.
3. Bastide M.F., et al. Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia. Neurobiol. Dis. 2013, 62C:179-192.
4. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol. 2000, 129(5):823-834.
5. Bonifati V., et al. Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 1994, 17(1):73-82.
6. Bouaboula M., et al. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol. 2005, 517(3):174-181.
7. Breidert T., et al. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 2002, 82(3):615-624.
8. Burgermeister E., et al. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol. Cell. Biol. 2007, 27(3):803-817.
9. Carta A.R. PPAR-gamma: therapeutic prospects in Parkinson's disease. Curr. Drug Targets 2013, 14(7):743-751.
10. Carta A.R., et al. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. Synapse 2002, 44(3):166-174.
11. Carta A.R., et al. Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. Exp. Neurol. 2010, 224(2):395-402.
12. Carta A.R., et al. Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience 2011, 194:250-261.
13. Cenci M.A., Konradi C. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog. Brain Res. 2010, 183:209-233.
14. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10(8):2694-2706.
15. Chang J.W., et al. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 1999, 88(2):617-628.
16. Cimini A., et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 2005, 130(2):325-337.
17. Collino M., Patel N.S., Thiemermann C. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther. Adv. Cardiovasc. Dis. 2008, 2(3):179-197.
18. Cullingford T.E., et al. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J. Neurochem. 1998, 70(4):1366-1375.
19. Dehmer T., et al. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 2004, 88(2):494-501.
20. Dekundy A., et al. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 2007, 179(1):76-89.
21. Ding Y., et al. Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(2):840-845.
22. Fasano S., et al. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(50):21824-21829.
23. Fegley D., et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 2005, 313(1):352-358.
24. Feige J.N., et al. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res. 2006, 45(2):120-159.
25. Fernandez-Espejo E., et al. Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function. Neuropsychopharmacology 2004, 29(6):1134-1142.
26. Ferrer B., et al. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur. J. Neurosci. 2003, 18(6):1607-1614.
27. Feyder M., Bonito-Oliva A., Fisone G. L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front. Behav. Neurosci. 2011, 5:71.
28. Fu J., et al. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 2005, 48(8):1147-1153.
29. Goetz C.G., et al. Placebo influences on dyskinesia in Parkinson's disease. Mov. Disord. 2008, 23(5):700-707.
30. Gonzalez-Aparicio R., Moratalla R. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson s disease. Neurobiol. Dis. 2013, 62C:416-425.
31. Gottwald M.D., Aminoff M.J. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann. Neurol. 2011, 69(6):919-927.
32. Graybiel A.M., et al. The basal ganglia and adaptive motor control. Science 1994, 265(5180):1826-1831.
33. Gregoire L., et al. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-dopa in parkinsonian monkeys. Parkinsonism Relat. Disord. 2009, 15(6):445-452.
34. Guan Q., et al. Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa. Neurosci. Lett. 2007, 426(1):64-68.
35. Herdegen T., Leah J.D. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res. Brain Res. Rev. 1998, 28(3):370-490.
36. Hoffmann B.R., et al. Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity. J. Med. Chem. 2012, 55(19):8260-8271.
37. Inestrosa N.C., Toledo E.M. The role of Wnt signaling in neuronal dysfunction in Alzheimer's disease. Mol. Neurodegener. 2008, 3:9.
38. Kathuria S., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 2003, 9(1):76-81.
39. Kiaei M., et al. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2005, 191(2):331-336.
40. Klotz L., et al. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J. Immunol. 2005, 175(8):4948-4955.
41. Lindner M.D., et al. Validation of a rodent model of Parkinson's disease: evidence of a therapeutic window for oral Sinemet. Brain Res. Bull. 1996, 39(6):367-372.
42. LoVerme J., et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther. 2006, 319(3):1051-1061.
43. Lundblad M., et al. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15(1):120-132.
44. Lundblad M., et al. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2004, 16(1):110-123.
45. Lundblad M., et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp. Neurol. 2005, 194(1):66-75.
46. Martinez A., et al. The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. Neurosci. Res. 2012, 72(3):236-242.
47. Moreno S., Farioli-Vecchioli S., Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004, 123(1):131-145.
48. Morgese M.G., et al. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp. Neurol. 2007, 208(1):110-119.
49. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356(24):2457-2471.
50. O'Sullivan S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol. 2007, 152(5):576-582.
51. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, xxvi:237. Academic Press, San Diego, (p. of plates). 4th ed.
52. Pinna A., et al. Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. Eur. J. Pharmacol. 2002, 446(1-3):75-82.
53. Ramanan S., et al. The PPARalpha agonist fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain irradiation. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75(3):870-877.
54. Rascol O., et al. Limitations of current Parkinson's disease therapy. Ann. Neurol. 2003, 53(Suppl. 3):S3-S12. (discussion S12-5).
55. Ricote M., et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391(6662):79-82.
56. Rodriguez-Rivera J., Denner L., Dineley K.T. Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. Behav. Brain Res. 2011, 216(1):255-261.
57. Rylander D., et al. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther. 2009, 330(1):227-235.
58. Santini E., et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J. Neurosci. 2007, 27(26):6995-7005.
59. Santini E., et al. Dopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism. J. Biol. Chem. 2012, 287(33):27806-27812.
60. Schintu N., et al. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci. 2009, 29(5):954-963.
61. Schrag A., Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain 2000, 123(Pt 11):2297-2305.
62. Schwartz R.H. Adolescent abuse of dextromethorphan. Clin. Pediatr. (Phila) 2005, 44(7):565-568.
63. Singh I.S., et al. Molecular cloning and characterization of the promoter region of the mouse regulatory subunit RII beta of type II cAMP-dependent protein kinase. Biochem. Biophys. Res. Commun. 1991, 178(1):221-226.
64. Stienstra R., et al. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology 2007, 148(6):2753-2763.
65. Thomas A., et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2004, 75(1):141-143.
66. Verhagen Metman L., et al. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov. Disord. 1998, 13(3):414-417.
67. Westin J.E., et al. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 2007, 62(7):800-810.
68. Winkler C., et al. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10(2):165-186.
69. Yoon S.O., Chikaraishi D.M. Tissue-specific transcription of the rat tyrosine hydroxylase gene requires synergy between an AP-1 motif and an overlapping E box-containing dyad. Neuron 1992, 9(1):55-67.
70. Yu S., et al. Retinoic acid induces neurogenesis by activating both retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta). J. Biol. Chem. 2012, 287(50):42195-42205.
71. Zhao Y., et al. Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J. 2006, 20(8):1162-1175.
72. Zhou Q.Y., Li C., Civelli O. Characterization of gene organization and promoter region of the rat dopamine D1 receptor gene. J. Neurochem. 1992, 59(5):1875-1883.